Latest News for: eaaci

Edit

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Killeen Daily Herald 15 Jun 2026
Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of ....
Edit

Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026

PR Newswire 15 Jun 2026
The results were reviewed in an oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place from June 12-15, 2026 in Istanbul, Turkey.
Edit

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 (Pharvaris NV)

Public Technologies 15 Jun 2026
"The data presented at EAACI continue to provide evidence supporting a potentially differentiated profile of deucrictibant in both the on-demand setting and the prophylactic setting," said Berndt Modig, Chief Executive Officer of Pharvaris.
Edit

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 (Upstream Bio Inc)

Public Technologies 14 Jun 2026
) ... WALTHAM, Mass., June 14, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq ... The findings were presented during an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey ... Total Symptom Score.
Edit

EAACI Calls for a "Vision Zero" Future Free from Allergy and Asthma Burden

Nasdaq Globe Newswire 12 Jun 2026
Leading allergy experts to convene in Istanbul to explore ...
Edit

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible ...

Nasdaq Globe Newswire 12 Jun 2026
Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido® (remibrutinib) met its ...
Edit

Stallergenes Greer Will Present New Evidence on Long-term Outcomes in Allergen Immunotherapy at EAACI 2026

Killeen Daily Herald 11 Jun 2026
Stallergenes Greer, a global leader in allergy care, will present new clinical evidence and scientific advances in ....
Edit

Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free ...

Nasdaq Globe Newswire 11 Jun 2026
... 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Istanbul, Turkey.
Edit

Stallergenes Greer will present new evidence on long-term outcomes in allergen immunotherapy at EAACI 2026 (Stallergenes Greer Ltd)

Public Technologies 11 Jun 2026
"EAACI 2026 is an exceptional forum for the global allergy community to exchange knowledge and advance the field ... Strong scientific presence at EAACI 2026 ... ABOUT THE EAACI CONGRESS ... EAACI is ...
Edit

Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap (ALK-Abelló A/S)

Public Technologies 11 Jun 2026
Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) 2026; 12-15 June 2026; Istanbul, Turkey ... Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) 2026; 12-15 June 2026; Istanbul, Turkey.
Edit

Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress (Apricot Capital)

Public Technologies 09 Jun 2026
... results for BW-20805 at the European Association of Allergy & Clinical Immunology (EAACI) 2026 Congress, being held on June 12-15, 2026 in Istanbul, Türkiye.
Edit

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Nasdaq Globe Newswire 08 Jun 2026
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning ... Abstracts accepted by EAACI include..
Edit

Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress

PR Newswire 08 Jun 2026
"We are pleased that the updated analysis from the ongoing Phase II data for BW-20805 has been selected for presentation at EAACI 2026.
Edit

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Nasdaq Globe Newswire 29 May 2026
... of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey.
Edit

Li et al (EAACI Beijing 2026) RAPIDe 3 TLR oral 27Apr2026 FINAL no QR (Pharvaris NV)

Public Technologies 09 May 2026
) ‌Efficacy and Safety of On-Demand Treatment of Hereditary Angioedema Attacfis With Oral Deucrictibant Immediate-Release Capsule.‌. Phase 3 RAPIDe-3 Trial Results. Philip H. Li, Marc A ... EAACI Beijing Allergy School 2026 & PUMCH Allergy Symposium ... 1 ... .

Article Search

tools
×
×
×
×